Powered by
MOMENTUM
MEDIA
MinterEllison has advised BARD1 Life Sciences on its recent $17 million capital raising.
Firm: MinterEllison (BARD1 Life Sciences).
Value: $17 million.
Area: Finance, corporate.
Key players: The MinterEllison team comprised partners Bart Oude-Vrielink and Sudharshan Senathirajah, associate Alexander Persano and solicitor Josh Carfi.
Deal significance: According to a statement provided by MinterEllison, the capital raising will help fund BARD1’s critical research and development of cancer diagnostics to improve patient outcomes.
“MinterEllison has assisted BARD1 Life Sciences Limited (BD1) on its institutional placement and share purchase plan, which are expected to raise a total of approximately $17 million,” the statement said.
“The capital raising will help fund BARD1’s further development and commercialisation of SubB2M tests for ovarian and breast cancer, commercialisation of EXO-NET products and other critical research.”
Commenting further, partner Sudharshan Senathirajah said: “We are pleased to have assisted BARD1 Life Sciences in this capital raising to support their important work. This raising will further BARD1’s life saving cancer research and product development. It provides both new and existing investors with the opportunity to invest in critical medical research and development.”
